



Announcement Summary

Entity name

CHIMERIC THERAPEUTICS LIMITED

Date of this announcement

Friday January 05, 2024

The +securities the subject of this notification are:

☒ Other

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
CHMAY	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	17,241,379	05/01/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

CHIMERIC THERAPEUTICS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

68638835828

1.3 ASX issuer code

CHM

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

5/1/2024



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ Other

Please specify

Unlisted options in Appendix 3B issued 4 January 2024

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class

ASX +security code and description

CHMAY : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

5/1/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

☒ Yes

Any other information the entity wishes to provide about the +securities the subject of this notification

Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Unlisted options in Appendix 3B issued 4 January 2024.

Issue details

Number of +securities

17,241,379

Were the +securities issued for a cash consideration?

☒ No

Please describe the consideration being provided for the +securities

Options issued as part of Placement announced 4 January 2024

Purpose of the issue

Other

Additional Details

Funds will be used to support the clinical trial pipeline and therapy portfolio.



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
CHM : ORDINARY FULLY PAID	725,840,586
CHMO : OPTION EXPIRING 31-MAR-2024	83,020,927

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CHMAC : OPTION EXPIRING 18-JAN-2024 EX \$0.30	4,957,897
CHMAD : OPTION EXPIRING 18-JAN-2025 EX \$0.20	2,750,000
CHMAT : OPTION EXPIRING 31-MAR-2024 EX \$0.255	15,000,000
CHMAAB : PERFORMANCE RIGHTS	9,086,413
CHMAY : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	168,991,905



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

17,241,379 options as part of Placement announced 4 January 2024.

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No